comparemela.com

Latest Breaking News On - ரெஹானா காந் - Page 1 : comparemela.com

FDP on Seismic Safety of Structures from October 4 – India Education | Latest Education News | Global Educational News

FDP on Seismic Safety of Structures from October 4 – India Education | Latest Education News | Global Educational News
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

Fighting the virus

Fighting the virus July 3, 2021 Long queues outside vaccination centres show that a large number of people are getting their vaccine doses. This is a good sign. However, it is also important to note that a majority of people are those who have to travel abroad or who are asked by their employers to get vaccinated. There are many people who are not getting vaccinated because they still believe in the ridiculous conspiracy theories that are all over social media. The healthcare authorities should launch awareness campaigns to educate people. Also, it is equally important to reach out to people living in rural areas. Previously, these people didn’t believe that the coronavirus is real. We cannot get rid of the virus unless we vaccinate a large number of people. At present, the government’s efforts are mostly focused on urban cities. The authorities must set up vaccination centres in small villages and other remote areas to save people from this deadly virus.

COVID-19 treatment: 5 Indian drugmakers ink pacts with Merck for molnupiravir

COVID-19 treatment: 5 Indian drugmakers ink pacts with Merck for molnupiravir The company, known as Merck in the US and Canada, has inked pacts with Cipla, Dr Reddy s Laboratories, Sun Pharma, Hetero Labs, and Emcure Pharmaceuticals BusinessToday.In | April 28, 2021 | Updated 12:19 IST MSD India is a wholly-owned subsidiary of Merck Sharp & Dohme (MSD) Drug firm MSD announced on Tuesday its decision to enter into voluntary licencing agreements with five Indian generic manufacturers to supply its investigational oral antiviral drug candidate molnupiravir , which is currently being studied for the treatment of COVID-19 patients. The company, known as Merck in the US and Canada, has inked pacts with Cipla, Dr Reddy s Laboratories, Sun Pharma, Hetero Labs, and Emcure Pharmaceuticals. MSD is in the process of developing molnupiravir in collaboration with Ridgeback Biotherapeutics.

MSD widens access to molnupiravir in India

MSD widens access to molnupiravir in India MSD widens access to molnupiravir in India 27 April 2021 | News Image credit- shutterstock.com MSD Pharmaceuticals, a wholly owned subsidiary of Merck Sharp & Dohme and known as Merck & Co., Inc., in the United States and Canada, has announced that the company has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufacturers. Molnupiravir is an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19. MSD is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. MSD has entered into these agreements to accelerate availability of molnupiravir in India and in other low- and middle-income countries (LMICs) following approvals or emergency authorization by local regulatory agencies.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.